The U.S. Supreme Court on Tuesday sided against more than 200 hospitals in a dispute over Medicare disproportionate share hospital [...] …
Articles by : Bella Czajkowski, National Correspondent
Recent Health Resources and Services Administration (HRSA) audits found that two drugmakers overcharged covered entities for their 340B drugs, fueling [...] …
The drug industry is bracing for the Trump administration’s planned tariffs on pharmaceutical products and ingredients, warning of supply chain [...] …
Minnesota covered entities will have additional 340B reporting requirements this year, but an extended deadline to submit that data, according [...] …
Tariffs on Pharmaceuticals Could Worsen Drug Shortages, Cause Disarray in 340B Prices, Advocates Say
President Donald Trump’s (R) plan to place tariffs on foreign pharmaceuticals could destabilize 340B drugs’ prices unless drugmakers absorb the [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
SK Life Science recently issued a refund notice for an epilepsy drug following a 340B price ceiling recalculation. The New [...] …
Johnson & Johnson (J&J) added Ustekinumab, the unbranded version of psoriatic arthritis treatment Stelara, to its 340B contract pharmacy restrictions [...] …
A shuttered Philadelphia-area hospital recently amended its legal filing in a class action case against CVS Health’s (CVS) contract pharmacy [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …